Lifesciences@Work : We help scientists build their business

OcellO: announcing strategic outsourcing agreement with Synthon Biopharmaceuticals

OcellO announces strategic outsourcing agreement with Synthon Biopharmaceuticals for compound testing in patient-derived tumour models.

OcellO announced continuation of the collaboration in discovery projects with Synthon Biopharmaceuticals whereby OcellO will provide services for high-content screening in patient-derived in vitro tissue models. OcellO will use panels of patient-derived 3D tumour models for testing of Synthon’s antibody-drug conjugates for its preclinical oncology research programs.

Patient-derived 3D tumour cultures bridge the gap between conventional cell line derivedin vitro models and in vivo models. Furthermore, OcellO’s image-based analysis of 3D tissues provides more detailed insight into the effects of ADCs on tumour tissues compared to conventional growth and killing assays.

Read the news item at Ocello website.

Read the Leiden BioSciencePark press release.

 

LS@W_FC-01| OcellO took part in the LS@W Venture Challenge Fall 2009.

(Its work name in 2009 was: 4DBio).

 

 

 

 

Tags: